Komori
K Pharma (4896) · InitiativeRestated

Strengthening the Legal Compliance and Risk Management Framework

First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023 – FY20252024: 120242025: 120252026: 12026
Same theme, other companies
Company-Wide Risk Management Framework through Audit and Internal ControlA theme 527 companies write about · 2 as a headwind · 523 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 534 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「We have established a Risk and Compliance Committee, chaired by the CFO and composed of representatives from each division, a full-time Audit & Supervisory Board member and outside attorneys. The committee meets once every quarter, establishes and operates company-wide risk-management and compliance systems, and regularly reports its activities to the Board of Directors.」

    The company continues its system of quarterly Risk and Compliance Committee meetings, company-wide risk management and reporting to the Board of Directors.
  2. FY2024RestatedAnnual report

    「We have established a Risk and Compliance Committee, chaired by the CFO and composed of representatives from each division, a full-time Audit & Supervisory Board member and outside attorneys. The committee meets once every quarter, establishes and operates company-wide risk-management and compliance systems, and regularly reports its activities to the Board of Directors.」

    The company continues to operate a system in which the Risk and Compliance Committee meets quarterly, manages legal compliance and risk, and reports to the Board of Directors.
  3. FY2023First statedAnnual report

    「We have established a Risk and Compliance Committee, chaired by the CFO, with representatives from each division, a full-time Audit & Supervisory Board member and outside attorneys as members. The committee meets once every quarter.」

    The company describes its management system through the Risk and Compliance Committee, basic internal-control policies, internal audits and reporting channels.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for K Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.